Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 10/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104819 | 0.81 | PTGS2 (0.49) | MAOAMAOB | |
| SCHEMBL7154393 | 0.66 | MAOA (0.42) | MAOAMAOBCYP2A6 | |
| SCHEMBL7154386 | 0.66 | MAOA (0.38) | MAOAMAOBCYP2A6CYP2C19CYP2C9 | |
| SCHEMBL9285273 | 0.64 | KCNA5 (0.59) | CYP2A6CYP2C19CYP2C9CYP2D6CYP2E1 | |
| SCHEMBL1651235 | 0.63 | CYP2A6 (0.55) | CYP2A6CYP2C19CYP2C9CYP2D6CYP2E1 | |
| SCHEMBL1650990 | 0.63 | CYP2A6 (0.51) | CYP2A6CYP2C19CYP2C9CYP2D6CYP2E1 | |
| SCHEMBL1422431 | 0.63 | KDM4E (0.60) | CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL1423179 | 0.62 | NPC1 (0.64) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL1652238 | 0.62 | KDM4E (0.49) | CYP2A6CYP2C19CYP2C9CYP2D6CYP2E1 | |
| SCHEMBL1652338 | 0.62 | CYP2A6 (0.50) | CYP2A6CYP2C19CYP2C9CYP2D6CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6465509-B2 | FOR THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | MERCK FROSST CANADA & CO. (CA) | 2002-10-15 | — | — | US | disclosed |
| US-20020058690-A1 | For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058690-A1 | For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent | PTGS1, PTGES2, PTGS2 | MAOA 1167/4885MAOB 1177/4885CYP2A6 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.